Rama Balamaran, MD
Dr. Rama Balaraman is a medical oncologist with Florida Cancer Affiliates in Ocala, Florida She specializes in the treatment of patients with lung cancer, malignant pleural mesothelioma, breast cancer, and other malignancies. Florida Cancer Affiliates is a community-based radiation oncology, medical oncology, and hematology practice. Its multidisciplinary team uses immunotherapy and targeted drug therapy in addition to traditional cancer treatments to allow patients access to advanced care in an outpatient setting. They also provide access to investigational drugs and therapies through clinical trials.[1]
Education and Career
Dr. Balaraman earned her medical degree at the Thanjavur Medical College in Thanjavur, India. She completed an internship and residency in medical oncology at St. Mary’s Health Center affiliated with St. Louis University School of Medicine in St. Louis, Missouri, and a fellowship at both the University of Missouri at Columbia in St. Louis, Missouri, and the Launceston General Hospital and Holman Clinic in Australia.[1]
Board-certified in both Hematology and Medical Oncology and a fellow of the Royal Australasian College of Physicians, Dr. Balaraman is a member of both the American Society of Clinical Oncology and the American Society of Hematology. She has hospital privileges at the Ocala Regional Medical Center, Advent Health Hospital where she is the chairman of the Lung Cancer Tumor Board, and West Marion Hospital.[1]
Research
Dr. Balaraman is actively involved in clinical research investigating immunotherapy and other novel protocols and therapies for treating malignant mesothelioma, lung cancer, and other thoracic malignancies. She has also published articles in peer-reviewed medical journals.
She is currently participating in several actively-recruiting clinical trials, including:[2]
Enrollment Status: Recruiting
Publish Date: January 19, 2024
Intervention Type: Drug
Enrollment Status: Recruiting
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drugs: BT8009, Nivolumab
Enrollment Status: Recruiting
Publish Date: January 16, 2024
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Enrollment Status: Recruiting
Publish Date: January 11, 2024
Intervention Type: Drug
Enrollment Status: Recruiting
Publish Date: August 11, 2022
Intervention Type: Procedure
Cardio-oncology: Capecitabine Can Sometimes be Heatbreaking Capecitabine-Induced Takotsubo Cardiomyopathy Case Report and Literature Review. Ramy Abdelmaseih, Anamarys Blanco, Randa Abdelmasih, Krutika Desai, Joshua Pothen, Jay Patel, Rama Balaraman>; Current Problems in Cardiology. 2021 Apr 3
A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report. Elio Paul Monsour, Joshua Pothen, Rama Balaraman>; Cureus. 2019 Oct 2
Effects of Lagenaria sicessaria fruit juice on lipid profile and glycoprotein contents in cardiotoxicity induced by isoproterenol in rats. Upaganlawar A, Balaraman R>; Toxicol Int. 2012-01-01
